SMS Pharmaceuticals targets 1.75x asset turnover in 2-3 years

SMS Pharmaceuticals Limited is targeting average net asset turnover of 1.75 times over the next two to three years, up from 1.46 times currently including capital work-in-progress, while planning to complete Rs 280 crore of capital expenditure by FY27. Management says the current capex round targets returns in the high-teens range.

How will SMS Pharmaceuticals raise asset turnover?

SMS Pharmaceuticals plans to raise average net asset turnover to 1.75 times over the next two to three years through a ramp-up of high-volume products, strategic partnerships and market-share gains in selected active pharmaceutical ingredients. The current turnover level is 1.46 times, and management specifies that this figure includes capital work-in-progress, or CWIP.

The 1.75-times objective is 0.29 times above the current level. Management does not identify FY27 as the deadline for the turnover target: the presentation gives a two-to-three-year timeframe for asset turnover and separately says Rs 280 crore of capex is to be completed by FY27. This makes utilisation of the expanded asset base a central measure of execution.

SMS Pharmaceuticals identifies three revenue-side drivers. It is targeting the number-one global position in anti-inflammatory products, aims to generate additional revenue through its arrangement with Chemo, and seeks market-share wins in key active pharmaceutical ingredients. These are management objectives, and the presentation does not disclose projected revenue or volume from the Chemo arrangement, anti-inflammatory portfolio or individual market-share gains.

What is included in the Rs 280 crore capex plan?

SMS Pharmaceuticals plans to complete Rs 280 crore of capital expenditure by FY27, with brownfield projects representing 89% of the project mix and greenfield activity representing 11%. The programme is directed towards capacity expansion for existing active pharmaceutical ingredients, capacity for the new product pipeline and land acquisition for a greenfield project.

Land acquisition is in process for the greenfield project, according to the presentation. SMS Pharmaceuticals does not provide project-level costs, planned capacities, commissioning dates or the location of the greenfield project. As a result, the disclosed FY27 completion milestone applies to the overall Rs 280 crore spend rather than to individual facilities or products.

Management says SMS Pharmaceuticals completed one capex cycle over the last three to four years and is now focused on asset utilisation to deliver what it calls best-in-class returns. For the current capex round, management targets returns in the high-teens range. The presentation does not define the return measure as return on capital employed, return on equity or another metric, so it does not directly connect that range to the 1.75-times asset-turnover target.

Which products and operating measures support the plan?

SMS Pharmaceuticals is supporting the capacity plan with 10 targeted drug master file, certificate of suitability and dossier filings in FY27. Drug master file is abbreviated as DMF, while certificate of suitability is abbreviated as CEP. The company also says research and development investment will increase over the next 15 months.

The product pipeline includes anti-inflammatory, anti-diabetic and anti-depressant products where lab-scale development and commercial validation are completed. Anti-hypertensive, antipsychotic and ulcerative-colitis products have completed lab-scale development and validation. The presentation does not state regulatory approval dates, commercial launch dates, addressable markets or sales expectations for these six therapeutic categories.

Backward integration is the supply-chain mechanism SMS Pharmaceuticals identifies alongside its product plans. The company says it has backward integrated several products and can backward integrate molecules to help protect gross margins. It also cites lower dependency on China for raw materials, protection against market fluctuations, a cost-competitive structure and improved reliability.

The presentation links backward integration to gross-margin protection and research and development capabilities through a learning-by-doing culture. This is distinct from the revenue levers of Chemo-related sales and share gains in key active pharmaceutical ingredients. SMS Pharmaceuticals does not provide a count of backward-integrated molecules, a raw-material sourcing split or a gross-margin target associated with the Rs 280 crore programme.

What financial performance frames the utilisation target?

SMS Pharmaceuticals reported consolidated revenue from operations of Rs 523.05 crore in H1FY27, up 19% from Rs 438.48 crore in H1FY26. Gross profit increased 28% to Rs 185.77 crore, while gross margin rose to 36% from 33%, a change of 239 basis points. One basis point equals one-hundredth of a percentage point.

Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 24% to Rs 108.60 crore in H1FY27 from Rs 87.73 crore in H1FY26. EBITDA margin increased to 21% from 20%, while profit after tax after share of associate profit or loss rose 33% to Rs 60.75 crore from Rs 45.80 crore. The corresponding profit margin increased to 12% from 10%.

The quarterly comparison showed faster sequential growth in Q2FY27. Revenue was Rs 316.08 crore, 53% above Rs 206.96 crore in Q1FY27 and 30% above Rs 242.43 crore in Q2FY26. Q2FY27 EBITDA was Rs 67.65 crore, up 40% year on year, and reported profit after tax was Rs 39.57 crore, up 57% from Rs 25.13 crore.

The H1FY27 balance sheet shows the expanding asset base that must be utilised. Property, plant and equipment rose to Rs 579.47 crore from Rs 531.22 crore at FY26, while CWIP increased to Rs 138.26 crore from Rs 121.64 crore. Total assets were Rs 1,460.65 crore at H1FY27 versus Rs 1,362.44 crore at FY26, and inventories rose to Rs 377.74 crore from Rs 351.20 crore.

Conclusion

SMS Pharmaceuticals is setting a defined operating objective: raise average net asset turnover from 1.46 times to 1.75 times over two to three years while completing a Rs 280 crore capex programme by FY27. The strategy combines predominantly brownfield expansion, higher-volume products, 10 targeted FY27 regulatory filings, partnership-led revenue and backward integration intended to support supply reliability and gross margins.

The next disclosed milestones are completion of the Rs 280 crore capex programme by FY27, the 10 targeted DMF, CEP and dossier filings in FY27, and increased research and development investment over the next 15 months. Progress will depend on whether the expanded capacity, new pipeline and Chemo arrangement translate into the utilisation required for the 1.75-times turnover target and management's stated high-teens return objective.